Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients. Unfortunately, resistance to targeted therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jing, Ji, Qing, Li, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522158/
https://www.ncbi.nlm.nih.gov/pubmed/34663410
http://dx.doi.org/10.1186/s13046-021-02130-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522158/
https://www.ncbi.nlm.nih.gov/pubmed/34663410
http://dx.doi.org/10.1186/s13046-021-02130-2

Ejemplares similares